a Department of Pharmaceutical Technology, Faculty of Pharmacy , Hacettepe University , Ankara , Turkey.
b Department of Pharmaceutical Technology, Faculty of Pharmacy , Erciyes University , Kayseri , Turkey.
J Microencapsul. 2017 Nov;34(7):659-666. doi: 10.1080/02652048.2017.1375039. Epub 2017 Sep 13.
The blood-brain barrier (BBB) is the major problem for the treatment of central nervous system diseases. A previous study from our group showed that the brain-targeted chitosan nanoparticles-loaded with large peptide moieties can rapidly cross the barrier and provide neuroprotection. The present study aims to determine the efficacy of the brain-targeted chitosan nanoparticles' uptake by the human BBB cerebral microvessel endothelial cells (hCMECs) and to investigate the underlying mechanisms for enhanced cellular entry. Fluorescently labelled nanoparticles either conjugated with antibodies recognising human transferrin receptor (anti-TfR mAb) or not were prepared, characterised and their interaction with cerebral endothelial cells was evaluated. The antibody decoration of chitosan nanoparticles significantly increased their entry into hCMEC/D3 cell line. Inhibition of cellular uptake by chlorpromazine indicated that the anti-TfR mAb-conjugated nanoparticles were preferentially cell internalised through receptor-mediated endocytosis pathway. Alternatively, as primarily observed with control chitosan nanoparticles, aggregation of nanoparticles may also have induced macropinocytosis.
血脑屏障(BBB)是治疗中枢神经系统疾病的主要障碍。我们之前的研究表明,载有大肽段的靶向脑部的壳聚糖纳米粒可以迅速穿透血脑屏障并提供神经保护。本研究旨在确定脑靶向壳聚糖纳米粒被人血脑屏障脑微血管内皮细胞(hCMEC)摄取的效果,并研究增强细胞内吞作用的潜在机制。制备了荧光标记的纳米粒,要么与识别人转铁蛋白受体的抗体(抗-TfR mAb)偶联,要么不偶联,并对其与脑内皮细胞的相互作用进行了评价。壳聚糖纳米粒的抗体修饰显著增加了它们进入 hCMEC/D3 细胞系的能力。氯丙嗪的细胞摄取抑制表明,抗-TfR mAb 偶联的纳米粒主要通过受体介导的内吞作用途径被优先内化。或者,如主要观察到的壳聚糖纳米粒,纳米粒的聚集也可能诱导巨胞饮作用。